Acquisition, Human Genome Sciences | featured news

Exclusive: GSK set for Human Genome takeover

GlaxoSmithKline is expected to announce a deal to buy Human Genome Sciences for about $2.8 billion as soon as Monday, ending a three-month hostile pursuit of the U.S. biotech company on friendly terms after sweetening its offer.

 

GlaxoSmithKline appeals directly to Human Genome Sciences shareholders in buyout dispute

British drugmaker GlaxoSmithKline said Wednesday it will no longer wait for Human Genome Sciences to consider an acquisition offer and instead appealed directly to the Rockville firm’s shareholders to accept its $13-per-share asking price.

 

Subscribe to this RSS topic: Syndicate content